12:00 AM
 | 
Oct 04, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

T-20: Phase II

TRMS and partner Roche reported 16-week data from a Phase II study of 55 patients previously treated with a median of 11 antiretroviral agents. Of these patients, 93 percent and 87 percent had genotypic...

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >